Semaglutide

Semaglutide
Semaglutide
Semaglutide
Semaglutide

Semaglutide

Min.Order / FOB Price:Get Latest Price

1 Kilogram

FOB Price: USD 105.0000

  • Min.Order :1 Kilogram
  • Purity: 99%
  • Payment Terms : T/T,Other

Keywords

Semaglutide Peptide 910463-68-2

Quick Details

  • Appearance:White powder
  • Application:For Pharmaceutical using
  • PackAge:Foil bag or drum
  • ProductionCapacity:100000|Kilogram|Day
  • Storage:Storage in cool dry place
  • Transportation:25kg/cardboard drum with two inner bags 1kg/aluminum foil bag Or according to customer's request

Superiority:

Xi'an ZB Biotech Co., Ltd is specialized in researching, producing and selling herbal extract and API powder, which are mainly used in nutraceutical, cosmetic, beverage and food additives etc.

Owing plant base, extracting and purifying in GMP workshop, concentrating on the quality and cost each link. That XAZB Biotech is aiming of benefiting the world with lowest price but best products.

We are keeping overcritical on the quality and persisting in the profession all the time. XAZB owns two standardized production workshops, advanced multifunction extractors and juice concentrate equipment, covering 12,000m2. annual dried material processed 950MT, monthly production ability 60MT. 32 scientists are in R&D team. We have strict QC standards and perfect quality guarantee system, GMP certified, also FDA, ISO9001 and Halal certified. 

We also build an integrative marketing center in Xi'an city, China, involving in research, test, sale and service. With full qualification and exporting experience, our products are widely sold to more than 40 countries from Europe, America, Southeast Asia, Oceania and so on

 

Details:

 

semaglutide is a new generation GLP-1 (glucagon-like peptide-1) analogue developed by NovoNordisk, a Danish company. Semaglutide is a long-acting formulation based on the basic structure of Liraglutide, which is more effective in the treatment of type 2 diabetes. Novo Nordisk has completed six PChemicalbookhaseIIIa studies for its Somarutide injection and submitted an application to the U.S. Food and Drug Administration (FDA) on December 5, 2016 for New Drug registration for its once-a-week Somarutide injection. An application for Marketing Authorization (MAA) has also been submitted to the European Medicines Agency (EMA). A once-daily oral formulation of Sommarutide, on the other hand, is currently in phase III.

Weight Loss

View All
Visit Store

You Might Also Like

Related Searches

Contact Supplier

Confirm to collect the product to my collection?

OKCancel

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View